{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:17:59Z","timestamp":1779931079819,"version":"3.53.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T00:00:00Z","timestamp":1483056000000},"content-version":"vor","delay-in-days":2920,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2009]]},"DOI":"10.1016\/j.jiph.2009.04.003","type":"journal-article","created":{"date-parts":[[2009,5,30]],"date-time":"2009-05-30T09:31:50Z","timestamp":1243675910000},"page":"62-73","source":"Crossref","is-referenced-by-count":6,"title":["Antibiotic therapeutic options for infections caused by drug-resistant Gram-positive cocci"],"prefix":"10.1016","volume":"2","author":[{"given":"K.","family":"Banwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Senok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.O.","family":"Rotimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jiph.2009.04.003_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious Gram-positive infections","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2009.04.003_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.mib.2007.07.004","article-title":"Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureusEnterococcus spp. and Pseudomonas aeruginosa in 2010","author":"Nordmann","year":"2007","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.jiph.2009.04.003_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1368-5031.2005.00885.x","article-title":"Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections","volume":"60","author":"Kern","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jiph.2009.04.003_bib4","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/13543784.16.8.1159","article-title":"Synthetic lipopeptides: a novel class of anti-infectives","volume":"16","author":"Jerala","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jiph.2009.04.003_bib5","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.7.10.1381","article-title":"Update on daptomycin: the first approved lipopeptide antibiotic","volume":"7","author":"Lee","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jiph.2009.04.003_bib6","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/AAC.35.9.1710","article-title":"Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs","volume":"35","author":"Hanberger","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jiph.2009.04.003_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1469-0691.2006.01342.x","article-title":"The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria","volume":"12","author":"Rybak","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2009.04.003_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1128\/AAC.46.1.31-33.2002","article-title":"Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers","volume":"46","author":"Wise","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib11","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cbi.2004.08.004","article-title":"An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes","volume":"150","author":"Oleson","year":"2004","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.jiph.2009.04.003_bib13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","article-title":"In vitro activities of daptomycin against 2789 clinical isolates from 11 North American medical centers","volume":"45","author":"Barry","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkh143","article-title":"Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms","volume":"53","author":"Streit","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib15","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1128\/AAC.47.6.1968-1971.2003","article-title":"In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/AAC.47.1.337-341.2003","article-title":"In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates","volume":"47","author":"Goldstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib17","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2009.04.003_bib19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.idc.0000144898.12957.eb","article-title":"Daptomycin versus Ciprofloxacin in the treatment of complicated urinary tract infection due to Gram-positive bacteria","volume":"12","author":"Kurt","year":"2004","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.jiph.2009.04.003_bib20","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4140\/TCP.n.2004.614","article-title":"Daptomycin: the first approved lipopeptide antimicrobial","volume":"19","author":"Guay","year":"2004","journal-title":"Consult Pharm"},{"key":"10.1016\/j.jiph.2009.04.003_bib22","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2146\/ajhp050487","article-title":"Tigecycline: a new glycylcycline antimicrobial agent","volume":"63","author":"Kasbekar","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiph.2009.04.003_bib23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.26.8.1099","article-title":"Tigecycline: first of a new class of antimicrobial agents","volume":"26","author":"Rose","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiph.2009.04.003_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1471-4892(01)00081-9","article-title":"Glycylcyclines: third-generation tetracycline antibiotics","volume":"1","author":"Chopra","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jiph.2009.04.003_bib25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","volume":"56","author":"Pankey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.clinthera.2006.08.011","article-title":"Tigecycline: a glycylcycline antimicrobial agent","volume":"28","author":"Doan","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jiph.2009.04.003_bib27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jac\/dkh125","article-title":"Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA","volume":"53","author":"Bauer","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib28","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.40.9.2226","article-title":"Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection","volume":"40","author":"Bergeron","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib29","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue and body fluid concentrations of tigecycline after a single 100mg dose","volume":"58","author":"Rodvold","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clinthera.2005.01.007","article-title":"Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms","volume":"27","author":"Garrison","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.jiph.2009.04.003_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.diagmicrobio.2005.05.003","article-title":"Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000\u20132004)","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diagmicrobio.2005.05.004","article-title":"Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia","volume":"52","author":"Fritsche","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diagmicrobio.2005.05.002","article-title":"Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit","volume":"52","author":"Sader","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.jiph.2009.04.003_bib34","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin\u2013aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jiph.2009.04.003_bib35","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijsu.2005.03.011","article-title":"Tigecycline is efficacious in the treatment of complicated intra-abdominal infections","volume":"3","author":"Fomin","year":"2005","journal-title":"Int J Surg"},{"key":"10.1016\/j.jiph.2009.04.003_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/sur.2005.058","article-title":"Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: evidence for pooled clinical studies comparing tigecycline with imipenem\u2013cilastatin","volume":"8","author":"Mallick","year":"2007","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.jiph.2009.04.003_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.diagmicrobio.2008.09.001","article-title":"Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin","volume":"63","author":"Bergallo","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.7326\/0003-4819-138-2-200301210-00015","article-title":"Linezolid: the first oxazolidinone antimicrobial","volume":"138","author":"Moellering","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jiph.2009.04.003_bib40","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1128\/AAC.41.10.2127","article-title":"The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin","volume":"41","author":"Lin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib41","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria","volume":"42","author":"Swaney","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib42","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiph.2009.04.003_bib43","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.47.9.2775-2780.2003","article-title":"Pharmacokinetics of linezolid in subjects with renal dysfunction","volume":"47","author":"Brier","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib44","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jac\/46.6.931","article-title":"Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group","volume":"46","author":"Henwood","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0195-6701(03)00145-2","article-title":"Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents","volume":"54","author":"Johnson","year":"2003","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jiph.2009.04.003_bib46","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1179\/joc.2005.17.6.607","article-title":"In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait","volume":"17","author":"Al Sweih","year":"2005","journal-title":"J Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1179\/joc.2003.15.2.113","article-title":"Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria","volume":"15","author":"Phillips","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1345\/aph.1H307","article-title":"Linezolid for the treatment of patients with central nervous system infection","volume":"41","author":"Ntziora","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jiph.2009.04.003_bib49","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/00365540110080467","article-title":"Linezolid for the treatment of central nervous system infections in neurosurgical patients","volume":"34","author":"Viale","year":"2002","journal-title":"Scand J Infect Dis"},{"issue":"4","key":"10.1016\/j.jiph.2009.04.003_bib50","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/314080","article-title":"Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid","volume":"31","author":"Plouffe","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib51","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/AAC.44.12.3408-3413.2000","article-title":"Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections","volume":"44","author":"Stevens","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib52","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijantimicag.2005.09.003","article-title":"Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA)","volume":"26","author":"Itani","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2009.04.003_bib53","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib54","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib55","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"(PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib56","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1128\/AAC.47.6.1824-1831.2003","article-title":"Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies","volume":"47","author":"Rubinstein","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib57","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1212\/01.wnl.0000201313.24970.b8","article-title":"Linezolid-associated toxic optic neuropathy","volume":"66","author":"Rucker","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jiph.2009.04.003_bib58","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.285.10.1291","article-title":"Linezolid and reversible myelosuppression","volume":"285","author":"Green","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2009.04.003_bib59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(05)70051-7","article-title":"Mechanisms of action of newer antibiotics for Gram-positive pathogens","volume":"5","author":"Hancock","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. A","key":"10.1016\/j.jiph.2009.04.003_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/39.suppl_1.7","article-title":"Inhibition of protein synthesis by streptogramins and related antibiotics","volume":"39","author":"Cocito","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib61","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/1389450023347678","article-title":"Streptogramin antibiotics: mode of action and resistance","volume":"3","author":"Johnston","year":"2002","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jiph.2009.04.003_bib62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00003088-200443040-00003","article-title":"Clinical pharmacokinetics of quinupristin\/dalfopristin","volume":"43","author":"Bearden","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiph.2009.04.003_bib63","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0732-8893(98)80002-3","article-title":"Antimicrobial activity of quinupristin\u2013dalfopristin (RP 59500 Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada","volume":"31","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0732-8893(98)00108-4","article-title":"Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds","volume":"33","author":"Jones","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib65","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1517\/14656566.3.9.1341","article-title":"Quinupristin\/dalfopristin","volume":"3","author":"Blondeau","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jiph.2009.04.003_bib66","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003495-199958060-00008","article-title":"Quinupristin\/dalfopristin: a review of its use in the management of serious gram-positive infections","volume":"58","author":"Lamb","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2009.04.003_bib67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/jac\/44.2.263","volume":"44","author":"Nichols","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib68","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jac\/44.2.251","article-title":"The efficacy and safety of quinupristin\/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium Synercid Emergency-Use Study Group","volume":"44","author":"Moellering","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib69","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/ajrccm.161.3.9904115","article-title":"Treatment of gram-positive nosocomial pneumonia Prospective randomized comparison of quinupristin\/dalfopristin versus vancomycin Nosocomial Pneumonia Group","volume":"161","author":"Fagon","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. A","key":"10.1016\/j.jiph.2009.04.003_bib70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/44.suppl_1.25","article-title":"Quinupristin\/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections","volume":"44","author":"Moellering","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib71","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: a novel antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jiph.2009.04.003_bib72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2003.09.004","article-title":"Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates","volume":"48","author":"Streit","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib73","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1021\/ja043849e","article-title":"Differential inhibition of Staphylococcus aureus PBP2 by glycopeptide antibiotics","volume":"127","author":"Leimkuhler","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jiph.2009.04.003_bib74","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2009.04.003_bib75","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib76","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2009.04.003_bib77","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187603410900032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187603410900032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T13:07:39Z","timestamp":1558357659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187603410900032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"alternative-id":["S187603410900032X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2009.04.003","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]}}}